End-of-day quote
Taiwan S.E.
03:30:00 17/05/2024 am IST
5-day change
1st Jan Change
46.8
TWD
+1.96%
-1.06%
-18.47%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. cancelled the transaction announced on March 11, 2024
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced a private placement of not more than 15,512,000 common shares on March 11, 2024. The transaction has been approved by the shareholders of the company.
On the same day, Chunghwa Chemical Synthesis & Biotech Co., Ltd. cancelled the transaction.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
28/03
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. cancelled the transaction announced on March 11, 2024
11/03
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
13/11
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
11/23/11
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022, Payable on August 18, 2023
27/23/27
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022
30/23/30
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/23/15
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
31/23/31
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced a financing transaction
07/23/07
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
11/22/11
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
12/22/12
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Dividend, Payable on August 18, 2022
28/22/28
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Appointment of Kuan Arthur¡G as Independent Director
25/22/25
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Approves Cash Dividend for 2021
25/22/25
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
14/22/14
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
01/22/01
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
12/21/12
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
14/21/14
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend, Payable on August 18, 2021
01/21/01
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
15/21/15
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
30/21/30
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
13/20/13
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces the Change of Representative of the Company's Legal Person Director
05/20/05
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces the Change of the Chairman and General Manager
05/20/05
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd.(TSEC:1762) added to S&P Global BMI Index
21/20/21
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
More about the company
Last Close Price
46.8
TWD
Average target price
48
TWD
Spread / Average Target
+2.56%
Consensus
1st Jan change
Capi.
-18.47% 11Cr -2.32% 9.04TCr +3.68% 4.14TCr -10.90% 3.36TCr +58.05% 2.57TCr -19.56% 1.47TCr -9.06% 1.28TCr -11.34% 1.17TCr -43.53% 1.14TCr +3.75% 879.22Cr
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1